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Abstract
Background: The objective of this study was to investigate independent risk factors (RFs) connected with
healthcare-associated (HA) Clostridium difficile infection (CDI) in surgical patients, its frequency per surgical wards
and in-hospital-mortality at a single hospital.
Methods: Risk factors for the infection were prospectively assessed among surgical patients with laboratory
confirmed HA CDI and compared with a control group without HA CDI.
Results: The overall incidence rate of HA CDI was 2.6 per 10000 patient-days. Significant independent RFs for HA
CDI were the use of carbapenems (P = 0.007, OR: 10.62, 95% CI: 1.93–58.4), the admission to intensive care unit
(P = 0.004, OR:3.00, 95% CI:1.41–6.40), and the administration of 3rd generation cephalosporins (P = 0.014, OR:2.27,
95% CI:1.18–4.39). Patients with HA CDI had significantly higher in–hospital mortality compared to controls (P: 0.007;
OR: 8.95; 95% CI: 1.84–43.43).
Conclusions: CDI is an important HA infection in population of surgical patients and this study emphasizes the
importance of the wise use of antibiotics, and other infection control strategies in order to prevent HA CDI, and to
decrease the incidence and in-hospital mortality rate.
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Background
During the current century the epidemiology of Clostrid-
ium difficile (C.difficile) infections (CDI) has changed
rapidly, with increases noted in the incidence of diseases
internationally, and in the reports of CDI outbreaks
within healthcare institutions in the USA, Canada and
Europe. The increase of CDI incidence was partly associ-
ated with the epidemic emergence of a new C. difficile
ribotype 027, which was also described to cause more
severe infections [1]. CDI became one of the most com-
mon healthcare-associated (HA) infections in modern
medicine. CDI results in a wide spectrum of clinical con-
ditions, including an asymptomatic carrier state; mild,
self-limited diarrhea; pseudomembranous colitis; and
fulminant colitis. It is associated with the increased mor-
bidity, in-hospital mortality, prolonged hospitalization,
and increased costs. The main risk factors for CDI in-
clude the administration of antibiotics, patients older
than 65 years, multiple co-morbid conditions, previous
hospitalization, medical procedures, and long stay in
hospitals [2–4]. The reported incidence of HA CDI
varies according to the country, the size of institution and
ward location, the type of population studied [5–11].
Patients undergoing surgical procedures are at risk of the
postoperative HA CDI development. Most studies of risk
factors (RFs) for CDI in surgical patients have been con-
ducted in the USA or Western European countries, which
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are characterized by the well-developed healthcare systems
[8–10, 12]. In contrast, the burden of CDI in Serbia, a
country in socioeconomic transition and with a resource-
limited healthcare system, is less well studied [3, 11]. The
burden of CDI in surgical patients in Serbia is unclear.
The aim of this study was to investigate independent
RFs associated with HA CDI in surgical patients, its fre-
quency per surgical wards and in-hospital-mortality in a
tertiary healthcare centre in Serbia.
Methods
Patients and databases
The Military Medical Academy (MMA), Belgrade,
Serbia, a teaching hospital of the University of Defense,
is a 1200-bed tertiary healthcare centre divided into 27
departments. The department of Infection Control per-
forms continuous surveillance of the MMA patients.
The surveillance of HA infections, including CDI,
covered patients in surgical clinics of the MMA:
Urology, General Surgery, Orthopedics/Traumatology,
Neurosurgery, Maxillofacial Surgery, Plastic Surgery/
Burns, Vascular Surgery, Thoracic Surgery, Cardio
Surgery, Otorhinolaryngology, and Ophthalmology.
Through regular hospital surveillance of surgical
patients we prospectively identified all patients who had
new HA, laboratory confirmed postoperative CDI during
the study period, from 1st January 2011 to 31st Decem-
ber 2012. Reviewing the clinical chart information on
patient characteristics, RFs related to healthcare were
collected. We gathered data on the following variables:
intrinsic factors (existing at admission) sex, age, Diabetes
mellitus, malignancy, and factors related to healthcare
including previous hospitalization in other hospitals,
intensive care unit (ICU) admission, duration of treat-
ment in ICU, mechanical ventilation, nasogastric tubes,
previous use of corticosteroids, histamine-2-receptor
antagonists (H2RAs), proton-pump inhibitors (PPIs) and
antibiotics (number, type, and duration of used antibi-
otics). Also, data about in-hospital mortality were
recorded.
In the case–control study, every surgical patient with
HA CDI was compared with two control patients with-
out CDI. HA CDI was defined as diarrhea (≥3 daily)
which was acquired more than three days after admis-
sion to the surgical department and detection of C.
difficile toxins A and B in a stool sample, which was
derived more than three days after admission. Control
patients were matched to the cases according to the
inpatient ward, gender, age (±5 years), and date of surgi-
cal operation.
Microbiological testing
Microbiological testing was performed at the Institute of
Medical Microbiology at the MMA. Enzyme immunoassay
kits for C. difficile toxins A and B were used (BIOMER-
IEUX-VIDAS Clostridium difficile toxins A&B CDAB). Only
patients who had never been diagnosed with CDI at the
MMA were included in the control group, and only those
who had not been diagnosed with CDI before enrolling in
the study, were included in the case group, respectively.
The Research Ethics Board of the MMA approved the
research protocol. All study participants provided the
informed written consent.
Statistical analysis
Incidence rate (IR) was defined as the number of HA CDIs
per 10000 patient-days and per 1000 patients treated. The
rate of testing (TR) was defined as the number of C. difficile
toxin tests performed per 10000 patient-days. The in-
hospital mortality rate was defined as the number of deaths
per 100 patients. Data analyses were performed with SPSS,
version 21.0 (SPSS, Inc, Chicago, IL). Results were
expressed as the mean ± SD or as the proportion of the
total number of patients. The χ2 test or Fischer exact test
were used for categorical variables and relative risk, and
their corresponding 95% confidence intervals (CI) were cal-
culated. For parametric continuous variables, mean values
were compared using the Student t test. For nonparametric
continuous variables the Mann–Whitney U test was used.
RF independently associated with CDI were identified by
stepwise logistic regression analysis of variables selected by
univariate analysis, with a limit for enetering and removing
variables from the model at 0.05.
Results
During 2011–2012 in the MMA 29033 surgical patients
were treated during 255431 patient-days. A total of 67
surgical patients with CDI were registered (IR: 2.6 per
10000 patient-days or 2.3 per 1000 patients, TR: 8.5 per
10000 patient-days) (Table 1).
Demographic and clinical characteristics of patients in
the case and control groups according to ULRA are
shown in Table 2. MLRA identified three independent
RFs associated with CDI in surgical patients: the previ-
ous administration of carbapenems (P = 0.007, OR:10.62,
95% CI:1.93–58.4), the 3rd generation of cephalosporins
(P = 0.014, OR:2.27, 95% CI:1.18–4.39) and admission to
the ICU (P = 0.004, OR:3.00, 95% CI:1.41–6.40). Accord-
ing to the ULRA, PPIs usage was a significant RF for
HA CDI (P = 0.05), but it was not a significant independ-
ent RF according to MLRA (P = 0.051, OR:2.7, 95%
CI:1.00–7.19).
In hospital-mortality was significantly higher by 9-fold
in HA CDI compared to control (12% vs 1.5%, P: 0.007;
OR: 8.95; 95% CI: 1.84–43.43). Of 8 deaths in the case
group, 6 or 75% were in the older than 65.
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Discussion
Most of epidemiological data about CDI in surgical
patients have been limited to North America and West
Europe [8–10, 12]. This study provides data about IR,
RF and in-hospital-mortality of HA CDI in surgical
patients admitted to the tertiary healthcare centre in the
South East Europe.
The overall IR of HA CDI was 2.6 per 10000 patient-
days, varied by different wards from 0 in Neurosurgery to
more than 6 per 10000 patient-days in Orthopedics/Trau-
matology and Cardio Surgery. The overall TR was 8.5 per
10000 patient-days varied by different wards from 2.0 in
Otorhinolaryngology to 16.9 per 10000 patient-days in
Vascular Surgery. Our results of IR were similar to data
reported by a coordinating laboratory for Portugal (2.9 for
2011–2012 and 3.0 for 2012–2013), but lower than mean
IR of 7.0 of HA CDI (country range 0.7–28.7) in a
European, multicentre, prospective, biannual point-
prevalence study of CDI in hospitalized patients with diar-
rhea (EUCLID) (4). In our hospital we have the practice of
routine testing of all submitted diarrheal inpatient
samples, but our TR in surgical patients in the two-year
period was far lower than mean TR in European hospitals
(65.8 tests, country range 4.6–223.3) (4).
An association between female gender and CDI has been
reported by previous population-based studies from the
USA [5]. Similarly to the report of Rodrigues et al. [9], our
results showed no significant association between gender
and CDI. Advance age is an independent RF for CDI in
many studies [5, 9, 10]. RFs specific to older adults are fre-
quent interactions with healthcare systems and age-related
changes in physiology, including immune senescence and
changes of the gut microbiome [13]. In our study majority
of CDI occurred in patients older than 40 years and half in
patients older than 65 years. We did not analyze age and
sex in the model of MLRA because cases and controls were
matched according to those variables.
Among the main findings of this study are the identifi-
cation of significant independent RFs for CDI in surgical
patients, including carbapenems, admission to ICU and
the 3rd generation of cephalosporins. The disruption of
the normal flora caused by antibiotics allows C. difficile
to colonize and overgrow within the gastrointestinal
tract. Nearly all antibiotics have been implicated in CDI,
but certain classes seem to cause higher risk for CDI.
Stojanović confirmed in his study that all the groups of
antibiotics, except for tetracycline, and trimetoprim-
sulfamethoxazole, were statistically significant RFs for
CDI [3]. The administration of quinolones emerged as
the most important RF for CID in Quebec during an
epidemic caused by a hipervirulent strain of C. difficile
[14]. A recent study from England showed that restrict-
ing quinolones prescribing was associated with a decline
in incidence of CDI [15]. The majority of patients in our
study received at least one class of antibiotic. The third-
generation cephalosporins were the most commonly
used antibiotics in both groups and an independent RF
for CDI. The study of Korean authors showed that the
use of cephalosporins increased the risk for CDI [4].
Also, the use of carbapenems, in addition to having the
higher frequency in the case group, was an independent
RF for CDI in our study. The study of Metzger et al.
showed that carbapenems usage was associated with
CDI in ULRA, but didn't retain significance as an
independent RF in MLRA [16].
The admission to ICU was significantly associated with
CDI in our patients as reported before [4, 9]. Critically ill
patients in ICU share many of the RFs for developing CDI
such as: severe underlying diseases, antibiotic exposure,
gastric acid suppression with H2RAs or PPIs, the use of
mechanical ventilation, and nasogastric tubes [17].
However, in a meta-analysis, Kwok et al. demonstrated
the possible association between the PPI use and the
incident and recurrent CDI. This risk was further
Table 1 Incidence rates of Clostridium difficile infections in 11 surgical wards of Military Medical Academy during 2011–2012
Ward Hospital Inpatient Days/
Number of patients treated






Urology 39022/5968 1.5 1.0 6.7
General Surgery 42063/4358 1.7 1.6 6.4
Traumatology/Orthopaedics 44139/3716 6.1 7.2 12.5
Neurosurgery 22546/2639 0 0 4.4
Maxillofacial Surgery 16829/2242 0.6 0.4 2.4
Plastic Surgery and Burns 24019/2414 4.6 4.6 11.2
Vascular Surgery 20175/1631 1.5 1.8 16.9
Thoracic Surgery 12408/1191 0.8 0.8 7.3
Cardiosurgery 13842/827 6.5 10.9 14.5
Otorhinolaryngology 20388/4047 1.0 0.5 2.0
Overall 255431/29033 2.6 2.3 8.5
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increased by concomitant use of antibiotics and PPI,
whereas H2RAs may be less harmful [18]. In our study,
according to ULRA, both groups of patients received
H2RAs (59.7% of cases and 46.2% controls) more
frequently than PPIs (19.4% and 5.9%), but only PPIs sig-
nificantly increased the risk of CDI without being a signifi-
cant independent RF. Also, mice model demonstrated that
PPIs administration can increase the severity of CDI
induced by an antibiotic cocktail [19]. Medications that
suppress gastric acid have been associated with the
alteration of gastrointestinal flora and the increased
susceptibility to gastrointestinal infections [20].
The mortality rate in patients with CDI in this
study was 12.1% and significantly higher than in the
control group. Also, it is higher than it was reported
in Veterans Health Administration (12.1% vs 5.3%)
[8]. This difference is explained by the different levels
of healthcare and treatment of patients in hospitals in
Serbia and the USA.
Of 8 deaths in the case group, 6 or 75% were in the
older than 65. CDI was not the primary cause of death
but it was mentioned in the clinical chart information. A
systematic review of unfavorable outcomes of CDI (68
studies), based on publications from 1978 until 2013,
showed that mortality was associated with age, co-mor-
bidities, hypo-albuminemia, leucocytosis, acute renal
failure, and infection with ribotype 027 [21].
Last data from a European, multicentre, prospective,
biannual point-prevalence study of CDI showed that
overall prevalence of ribotype 027 has risen more than
three-fold (from 5% to 18%) and high endemicity of
ribotype 027 has shifted from the UK and Ireland in
2008, to Germany and Eastern Europe in 2012–13 [6, 7].
The study of Rupnik et al. analyzed PCR ribotype distri-
bution of 249 C. difficile isolates received for typing from
six hospital settings from South Europe (the MMA was
not included) in time period from 2008 to 2015 and
showed that PCR ribotype 027 and related ribotype 176
were detected in outbreaks in Croatia, Bosnia and
Herzegovina and Serbia [22]. Some PCR ribotypes are
more often associated with severe diseases and/or are
easily transmitted and linked to outbreaks. In our study
we did not know if all those cases were from the
outbreak because of the inability of laboratory pathogen
isolation and the impossibility of determining its ribotype.
Important limitation of this study is that CDI testing
was based on toxin A/B enzyme immunoassay (EIA) as
the only diagnostic procedure in laboratory (no EIA
detecting glutamate dehydrogenase, no nucleic acid
amplification tests, no isolation of C. difficile and detec-
tion of toxigenic isolates). This procedure has shown
poor sensitivity of less than 50% in studies of Shin [23]
and Swindells [24]. The meta-analysis of Crobach et al.
showed that no single test can be used as a stand-alone
Table 2 Distribution of cases and controls according to their
demographic and clinical characteristics: results of univariate
analysis
Variable Case N° (%) Controls N° (%) p value
n = 67 n = 134
Male 32 (47.8) 64 (47.8) 1.00
Age
≤ 40 2 (2.9) 5 (3.7) 0.786
41–64 32 (47.8) 58 (43.3) 0.547
≥ 65 years 33 (49.2) 71 (52.9) 0.618
Diabetes mellitus 10 (14.9) 15 (11.2) 0.451
Malignacy 14 (20.9) 22 (16.4) 0.436
Previous hospitalization 13 (19.4) 19 (14.1) 0.342
ICU admission 22 (32.8) 19 (14.1) 0.003
≥ 5 days in ICU 67 (100.0) 121 (90.3) 0.051
Nasogastric tube 5 (7.4) 1 (0.7) 0.032
Mechanical ventilation 4 (5.9) 0 (0.0) 0.032
Proton-pump inhibitors 13 (19.4) 8 (5.9) 0.005
H2 receptor antagonist 40 (59.7) 62 (46.2) 0.074
Corticosteroides 4 (5.9) 1 (0.7) 0.059
One antibiotic 32 (47.8) 85 (63.4) 0.035
Days of usage an antibiotic 5.13 ± 2.14 4.40 ± 2.27 0.120
Two antibiotics 20 (29.9) 27 (20.1) 0.128
Days of usage two antibiotics 5.85 ± 3.79 4.63 ± 2.13 0.167
Three antibiotics 9 (13.4) 5 (3.7) 0.017
Days of usage three antibiotics 7.89 ± 5.89 5.60 ± 2.07 0.423
Four antibiotics 4 (6.0) 2 (1.5) 0.103
Days of usage four antibiotics 8.75 ± 4.35 7.00 ± 2.83 0.642
Cephalosporins 1st gen. 15 (22.4) 33 (24.6) 0.726
Days of usage cephalosporins
1st gen.
1.15 ± 2.47 1.04 ± 2.16 0.742
Cephalosporins 2nd gen. 14 (20.9) 25 (18.7) 0.705
Days of usage cephalosporins
2nd gen.
1.18 ± 2.50 0.96 ± 2.25 0.537
Cephalosporins 3rd gen. 42 (62.7) 62 (46.3) 0.029
Days of usage cephalosporins
3rd gen.
4.39 ± 4.59 2.51 ± 3.25 0.001
Aminiglycosides 7 (10.4) 18 (13.4) 0.546
Days of usage
Aminoglycosides
0.91 ± 3.58 0.66 ± 2.10 0.528
Quinolones 6 (8.9) 4 (3.0) 0.080
Days of usage Quinolones 0.52 ± 1.76 0.16 ± 0.94 0.056
Sulfonamides 3 (4.5) 5 (3.7) 0.799
Days of usage Sulfonamides 0.25 ± 1.26 0.15 ± 0.86 0.491
Carbapenems 6 (9.0) 2 (1.5) 0.024
Days of usage Carbapenems 0.62 ± 2.10 0.10 ± 0.85 0.014
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test for diagnosed CDI as a result of inadequate positive
predictive values at low CDI prevalence [25]. C. difficile
toxins can degrade at room temperature and the quality
of CDI diagnostic also depends on transport time of the
samples in the respective settings of the MMA. Both,
the low rate of test performance in general and limita-
tions of diagnostic test system, which we used, make it
very likely that the actual incidence of CDI in our study
was markedly higher.
Another limitation is the possibility of confounding vari-
ables that were not examined in our study. Although con-
founding variables were chosen after an exhaustive search
of the literature, the potential for oversight and exclusion
does exist. We tried to find all of the data in order to gain
an understanding of the RF; we did not include some
parameters, namely the diagnosis upon admission, all co-
morbidities, durations of the hospital stays, PPIs exposure
in previous 30 days, the duration of PPIs and H2RA use,
and outpatient antibiotic use, and analyzing these factors
could have enhanced the relevance of our results. Further-
more, we did not evaluate the CDI cases and the controls
in relation to the sex, age and wards in which they had
undergone treatment, because CDI cases and controls
were matched according to them.
Another limitation is that we performed case–control
study and that we have small sample size.
The strengths of our study include its setting in a
teaching hospital, and its 2-year duration. ULRA and
MLRA strengthened the evidence.
Conclusions
The results of the present study are valuable in docu-
menting the relations between RFs and CDI in patients
undergoing surgery and contribute to improve quality of
health care. CDI is an important HA infection in popu-
lation of surgical patients and this study emphasizes the
importance of the wise use of antibiotics, and other
infection control strategies to prevent HA CDI, decrease
incidence and in- hospital mortality rate.
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